Fluocinolone acetonide micro-insert intravitreous implant - pSivida

Drug Profile

Fluocinolone acetonide micro-insert intravitreous implant - pSivida

Alternative Names: DF-277; FAI insert; Fluocinolone; Fluocinolone acetonide intravitreal insert; Iluvien; Injectable micro-insert - Alimera Sciences/pSivida; Medidur implant; Medidur-FA; NSC-92339; Ophthalmic implant - Alimera Sciences/pSivida

Latest Information Update: 21 Jul 2017

Price : $50

At a glance

  • Originator pSivida Inc
  • Developer Alimera Sciences; Johns Hopkins University; pSivida Inc
  • Class Anti-inflammatories; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Uveitis

Highest Development Phases

  • Marketed Diabetic macular oedema
  • Preregistration Uveitis
  • No development reported Dry age-related macular degeneration; Retinal vascular occlusion; Wet age-related macular degeneration

Most Recent Events

  • 19 Jul 2017 The United Kingdom Medicines and Healthcare Products Regulatory Agency approves the request to reduce the sample size in the phase IV Iluvien Registry Safety Study
  • 18 Jul 2017 pSivida and Alimera announces intention to submit regulatory applications for Uveitis in Middle East and Africa
  • 12 Jul 2017 Alimera announces intention to submit regulatory applications in 17 European Union countries for Uveitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top